LCNDG Rapid Review: Lenalidomide for 1st relapse multiple myeloma after bortezomib

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews NICE recommends the use of lenalidomide for relapsed multiple myeloma only in those who have received two or more prior therapies.   The best available evidence to support the use of lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma comes from two phase III studies (MM-009 and MM-010). Both trials compared lenalidomide/dexamethasone to dexamethasone alone, and both trials used a primary endpoint of time to disease progression. There was only a limited number of patients in the two phase III studies who match the criteria for this application for funding, i.e. following one prior line of therapy- bortezomib. The time to progression was significantly longer for lenalidomide/dexamethasone compared to dexamethasone alone for both trials.   No studies have directly compared lenalidomide with other chemotherapy agents in the relapsed setting. It is also not clear whether/if re-treatment with bortezomib after a suitable ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news